Dear Colleague:

There are two products that are new to the New York City (NYC) Vaccines for Children (VFC) program that we would like you to be aware of.

The measles-mumps-rubella (MMR) vaccine formulation, PRIORIX™ (GSK), is approved for use in individuals 12 months of age and older. It has been used for many years internationally. As with the other MMR formulation, M-M-R II® (Merck), each dose in the 2-dose series is 0.5 mL and is to be administered subcutaneously. PRIORIX and M-M-R II are fully interchangeable, and PRIORIX may be used for all indications for which MMR vaccination is recommended by the Advisory Committee for Immunization Practice (ACIP). The routine schedule includes the first dose at 12 through 15 months of age and the second dose at 4 through 6 years of age. MMR vaccine can be given concomitantly with any other vaccine that is indicated for the patient. Full ACIP recommendations for use of PRIORIX are available here. PRIORIX comes as a single-dose vial of lyophilized antigen component that needs to be reconstituted with the accompanying prefilled syringe of sterile water diluent. Before reconstituting, PRIORIX should be stored in the refrigerator, between 36° and 46°F (2° and 8°C). If not used immediately after reconstituting, it should be stored in the refrigerator, and used within 8 hours.

Also available for ordering is the pneumococcal 15-valent conjugate vaccine, PCV15 (VAXNEUVANCE™ [Merck]). PCV15 is indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older as an alternative to PCV13. Its use is expected to reduce pneumococcal disease incidence in children because it induces immunity against two additional disease-causing serotypes than does PCV13. It can be used interchangeably with PCV13, and should be administered according to the currently recommended PCV13 dosing and schedules. ACIP recommendations for use of PCV15 in children are available here. Storage instructions are the same as for PCV13—prior to reconstituting it is to be kept in the refrigerator (between 36° and 46°F [2° and 8°C]). If not used immediately after reconstituting, it should be stored in the refrigerator, and used within 8 hours.

Please review the vaccine codes that will need to be used to ensure proper reporting of these vaccinations to the Citywide Immunization Registry (CIR). The following table will help ensure correct reporting to the CIR:
For questions on any immunization-related issue, please call (347) 396-2400 or email nycimmunize@health.nyc.gov. We thank you for your continuing efforts at protecting NYC residents from vaccine-preventable diseases.

Sincerely,

Jane R. Zucker, MD, MSc
Assistant Commissioner
Bureau of Immunization

<table>
<thead>
<tr>
<th>Sale NDC11</th>
<th>CVX Code</th>
<th>CVX Description</th>
<th>CPT Code</th>
<th>Proprietary Name</th>
<th>Sale Labeler</th>
<th>MVX Code</th>
<th>VFC program available</th>
</tr>
</thead>
<tbody>
<tr>
<td>58160-0824-15</td>
<td>03</td>
<td>MMR</td>
<td>90707</td>
<td>PRIORIX</td>
<td>GlaxoSmithKline Biologics SA</td>
<td>SKB</td>
<td>Yes</td>
</tr>
<tr>
<td>00006-4329-03</td>
<td>215</td>
<td>Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF</td>
<td>90671</td>
<td>VAXNEUVANCE</td>
<td>Merck Sharp &amp; Dohme LLC</td>
<td>MSD</td>
<td>Yes</td>
</tr>
</tbody>
</table>